MAPK8 and Alzheimer disease: Additional evidence in support of this argument originates from in vivo and in vitro experiments with AD, wherein MAPKs subtypes, including p38 and c-Jun NH2 terminal kinase (JNK), are activated by Aβ-treated cultured astrocytes and cerebral cortex of rats [34].